Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medicenna Therapeutics Corp has presented promising preclinical results for two novel treatments at the Promise of Interleukin-2 Therapy Conference. Their IL-2 Super-antagonist, MDNA209, shows potential in treating autoimmune diseases by significantly improving survival rates in a GvHD animal model. Meanwhile, their targeted BiSKIT therapy, MDNA113, exhibited enhanced efficacy in tumors overexpressing IL-13Rα2, offering hope for hard-to-treat cancers.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.